Ebixa indications extended

The licensed indications for Ebixa (memantine) have been extended to allow its use in the treatment of moderate to severe Alzheimer's dementia. Previously, Ebixa's uses were limited to the treatment of moderately severe to severe Alzheimer's dementia.

The extension to Ebixa's licence follows a meta-analysis of patients with moderate to severe Alzheimer's dementia from six phase III, placebo-controlled, 6-month studies which showed that memantine had a significantly favourable effect in preventing worsening of cognitive, global and functional domains.

Memantine is an NMDA receptor antagonist that modulates the effects of pathologically elevated tonic levels of glutamate that may lead to neuronal dysfunction.

View Ebixa drug record

Further Information: Lundbeck Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

'Innovative' heart failure treatment recommended by NICE

'Innovative' heart failure treatment recommended by NICE

Dapagliflozin (Forxiga), the first SGLT2 inhibitor...

Drug price changes - live tracker

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Pregabalin linked to severe respiratory depression in absence of opioids

Pregabalin linked to severe respiratory depression in absence of opioids

The MHRA advises prescribers to consider adjustment...